Anti-Human CD20 (Ublituximab) (C3180-1.0mg)

CD20 is a transmembrane protein that is prominently present on the surface of B-cells from the early to mature stages, but notably absent on hematopoietic stem cells, pro-B cells, or plasma cells. Its significance lies in its role in B-cell functions such as activation and differentiation. It is a key target for monoclonal antibodies used in the treatment of B-cell- related diseases and autoimmune conditions. Monoclonal antibodies targeting CD20 have been widely used to treat B-cell lymphomas, leukemias, and autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. These antibodies work by selectively targeting and depleting B-cells that express CD20, thereby modulating the immune response and reducing inflammation. This targeted approach has shown promising results in managing various B-cell disorders and has significantly improved the prognosis for patients with these conditions1,2. TG-1101, also known as Ublituximab, is a monoclonal antibody that targets the CD20 antigen. This helps enhance the immune responses that can destroy B-cells expressing CD20. Ublituximab is currently being studied for its potential in treating B-cell disorders and autoimmune diseases. It has received its first global approval in the USA for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease3-5.